Aridis Pharmaceuticals

ARDS

Biotechnology · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$4,457

Exchange

Other OTC

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+496.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 3.1M (2018) → 18.8M (2022)

Winston Score History

The full picture

Aridis Pharmaceuticals is a small biotechnology company focused on developing antibody-based medicines to fight serious bacterial infections. Its main focus is on treating hospital-acquired infections, particularly in patients on ventilators or with weakened immune systems. The company is working on drugs that target dangerous bacteria like Pseudomonas aeruginosa and Staphylococcus aureus, which are often resistant to standard antibiotics.

Aridis does not yet sell approved products, so it currently generates little to no revenue and operates at a loss, which is typical for early-stage drug developers. The company is based in the United States and is very small, with a market cap near zero. Its pipeline relies on a proprietary antibody discovery platform, but the biggest risk it faces is the high failure rate of clinical-stage drug development — most experimental drugs never reach approval, and Aridis will need additional funding to advance its programs through costly clinical trials.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+99.6% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$26M/ year

↓ Declining (-32% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

9.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

$35,000 cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Aridis Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Profit after running costs

Operating Margin

-208.4%

Losing money on operations — -208.4%

Return on the money invested

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

>+1,000%

Fast-growing sales (>+1,000% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-89.4%

Burning cash (-89.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial